文献速递毛发、甲与色素性疾病

Brepocitinib治疗瘢痕性脱发的2a期临床试验

A phase 2a trial of brepocitinib for cicatricial alopecia.
PubMed 文献 · J Am Acad Dermatol · 2024-10-24

这是一项随机、安慰剂对照的2a期试验,纳入成人瘢痕性脱发患者,随机3:1接受brepocitinib 45mg每日或安慰剂24周,随后全部接受brepocitinib24周。

要点

  • Brepocitinib 45mg每日治疗24周显著降低瘢痕性脱发皮损CCL5表达。
  • 药物耐受性良好,并改善临床严重度评分。

核心结论

  • Brepocitinib在24周时显著降低CCL5表达且耐受良好,达到共同主要终点。
  • Brepocitinib降低炎症生物标志物表达并改善临床严重度,保持良好安全性。

研究设计与样本

  • 随机、安慰剂对照2a期试验,持续52周。
  • 成人(≥18岁)诊断为扁平苔藓毛囊炎、额部纤维性脱发或中央离心性瘢痕性脱发,按3:1随机接受brepocitinib 45mg每日或安慰剂24周,之后全部接受brepocitinib24周,安全性随访4周。
  • 在基线、第24周和第48周采集皮损头皮活检。

主要发现

  • Brepocitinib耐受良好并改善临床严重度评分。

关键数值与推荐

  • 共同主要终点为第24周皮损CCL5表达变化、纤维化相关标志物表达变化及安全性。

临床怎么用

  • Brepocitinib可能通过抑制TYK2/JAK1通路降低CCL5表达,改善瘢痕性脱发临床严重度。

局限性

  • 单剂量方案。
  • 安慰剂组样本量小。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cicatricial alopecias are chronic, progressive scarring hair-loss conditions. Molecular dysregulation is not fully understood, hindering treatment development. Th1/IFNγ signaling and Janus kinase dysregulation has shown involvement, providing rationale for this phase 2a trial with Tyrosine kinase 2/Janus kinase 1 inhibitor brepocitinib. METHODS: Randomized, placebo-controlled phase 2a trial spanning 52 weeks. Adults (≥18 years of age) with lichen planopilaris, frontal fibrosing alopecia, or central centrifugal cicatricial alopecia diagnosis were randomized 3:1 to brepocitinib 45 mg daily or placebo for 24 weeks, after which all patients received brepocitinib for another 24 weeks, with a safety follow up 4 weeks later. Lesional scalp biopsies were collected at baseline, week 24, and week 48. Coprimary endpoints were changes in lesional expression of C-C motif chemokine ligand (CCL5), changes in lesional expression of fibrosis-related markers, and safety at week 24. RESULTS: Patients receiving brepocitinib showed significant downregulation in CCL5 expression at week 24 (P = .004). Enrichment analysis of a subset of fibrosis markers showed trending upregulation in placebo patients (P < .1). Brepocitinib was well tolerated and improved clinical severity scores. LIMITATIONS: Single-dose regimen, small placebo group. CONCLUSION: Brepocitinib significantly reduces CCL5 expression and was well tolerated at week 24, meeting coprimary endpoints. Brepocitinib reduces inflammatory biomarker expression and improves clinical severity, while maintaining favorable safety profile.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. David E, Shokrian N, Del Duca E, et al. A phase 2a trial of brepocitinib for cicatricial alopecia. J Am Acad Dermatol. 2024. PMID: 39461505. doi:10.1016/j.jaad.2024.09.073

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。